CohBar News

CohBar, Inc. Announces Discovery of New Peptides in the Mitochondrial Genome Company Expands IP Portfolio with 25 New Provisional Patent Applications

Menlo Park, California – October 13, 2016 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat diseases associated with aging, today announced the discovery of a large number of new biologically active peptides encoded within the genome of the mitochondria, together with the filing of 25 new provisional patent applications. The company is evaluating these peptides as possible additions to its pipeline of MBTs, and expects to file additional patent applications going forward. read-more

CohBar Expands Its Executive Team with the Appointment of Simon Allen as Chief Executive Officer

MENLO PARK, CA – March 7, 2016 - CohBar, Inc., an innovative biotechnology company focused on developing mitochondria-based therapeutics (MBTs) to treat diseases associated with aging, today announced that Simon Allen has been appointed as the company’s Chief Executive Officer. Mr. Allen brings to CohBar more than 20 years of industry experience and success both as a scientist and a business executive. Prior to joining CohBar, Mr. Allen was a consultant to Solstice Biologics, after spending nearly five years as Chief Business Officer of Ambrx Inc. During his tenure at Ambrx, he established collaborations with Bristol-Myers Squibb, Merck, Astellas, Eli Lilly, Zhejiang Medicine and Zhejiang Hisun Pharmaceutical that realized over $120 million in non-dilutive funding and $1.5 billion in potential milestone payments. Prior to Ambrx, Mr. Allen was CEO of Kalypsys Inc., and Chief Commercial Officer of CovX Inc. (acquired by Pfizer). In the past, Mr. Allen has held business development positions at Nuvelo, Inc., SkyePharma PLC, and Corixa Corporation, and worked as a healthcare equities analyst at Burdett, Buckeridge & Young. Mr. Allen began his career as a Research Biologist at Gilead Sciences. He holds a B.Sc. degree in biochemistry and genetics from the University of Sydney and an M.B.A. from the Australian Graduate School of Management. read-more

CohBar Expands Its Scientific Staff With the Addition of Kent Grindstaff

MENLO PARK, CA - May 1, 2015 - CohBar, Inc., an innovative biotechnology company focused on developing mitochondria-based therapeutics (MBTs) to treat diseases associated with aging, today announced it has hired Kent Grindstaff as its Vice President of Biology. During his career, Mr. Grindstaff has held increasingly senior roles in the industry most recently as VP of Global Operations at SOLVO Biotechnology. An expert in the area of assay development, Mr. Grindstaff will design and manage the day to day development, validation, and application of new in vitro screens that can test the activity of our optimized compounds in his role as VP of Biology. read-more

CohBar, Inc. Adds Frank J. Calzone, Ph.D., to its Scientific Advisory Board

MENLO PARK, CA – April 8, 2015 - CohBar, Inc., an innovative biotechnology company focused on developing mitochondria-based therapeutics for diseases associated with aging, today announced the addition of Frank J. Calzone, Ph.D., to the company’s Scientific Advisory Board. Mr. Calzone has over 22 years of experience in the isolation and preclinical development of protein therapeutics for cancer and other diseases. He is a member of the UCLA Translational Oncology Research Laboratory (TORL) and his research specialties are tumor genomics and drug discovery. He also serves as Vice President of Discovery Research for REMD Biotherapeutics, a company focused on antibody therapies for diabetes and cancer. read-more

Kenneth C. Cundy Joins CohBar, Inc. as Chief Scientific Officer

PASADENA, CA - November 17, 2014 - CohBar, Inc., an innovative biotechnology company whose mission is to treat major diseases and extend healthy life spans through the discovery of novel Mitochondrial-Derived Peptides, today announced it has hired Kenneth C. Cundy, Ph.D., as its Chief Scientific Officer. In his role as CSO, Dr. Cundy is responsible for CohBar's scientific research, development, planning and operations. read-more

CohBar, Inc. Appoints Marc Goldberg to its Board of Directors

PASADENA, CA - November 3, 2014 - CohBar, Inc., an innovative biotechnology company whose mission is to treat major diseases and extend healthy life spans through the discovery of novel Mitochondrial-Derived Peptides, today announced the appointment of Marc Goldberg, JD, MBA to the Company's Board of Directors. Mr. Goldberg is a Managing Director at BioVentures Investors, a life science focused venture and private equity investment firm that he co-founded in 1997. read-more

CohBar, Inc. Appoints Albion J. Fitzgerald as Chairman of the Board of Directors

PASADENA, CA – July 23, 2014 - CohBar, Inc., an innovative biotechnology company whose mission is to treat major diseases and extend healthy life spans through the discovery of novel Mitochondrial-Derived Peptides, today announced the appointment of Albion J. Fitzgerald as Chairman of the company's Board of Directors. Mr. Fitzgerald brings extensive experience to the role of Chairman, with over twenty five years of executive level and public company experience. read-more

CohBar, Inc. Hires Jeffrey F. Biunno as Chief Financial Officer

PASADENA, CA – October 31, 2013 - CohBar, Inc., an innovative biotechnology company whose mission is to treat major diseases and extend healthy life spans through the discovery of novel Mitochondrial-Derived Peptides, today announced the addition of Jeffrey F. Biunno as its Chief Financial Officer. In his role as CFO, Mr. Biunno will oversee CohBar's financial, budgetary, treasury and human resources functions. Mr. Biunno is a certified public accountant. read-more

CohBar, Inc. Appoints Jon L. Stern as Chief Executive Officer

PASADENA, CA – October 30, 2013 - CohBar, Inc., an innovative biotechnology company whose mission is to treat major diseases and extend healthy life spans through the discovery of novel Mitochondrial-Derived Peptides, today announced the appointment of Jon L. Stern as its Chief Executive Officer. Mr. Stern brings to the company over 25 years of experience as an entrepreneur and senior executive of growth stage companies. read-more

Alzheimer’s Drug Discovery Foundation Awards Grant to Cohbar to Develop a Novel Peptide Therapeutic for Alzheimer’s Disease

NEW YORK, March 6th, 2013 – The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded $205,260 in funding to CohBar Inc. to develop a novel mitochondrial peptide for the treatment of Alzheimer's disease (AD). The peptide has been shown to have neuro-protective effects against a variety of AD-related toxic insults, including amyloid-beta. read-more